Gilead To Present New Trodelvy Data At The IASLC 2024 World Conference On Lung Cancer
Gilead To Present New Trodelvy Data At The IASLC 2024 World Conference On Lung Cancer
-Data Span Multiple Types of Lung Cancer and Lines of Therapy-
-数据跨多个类型的肺癌和治疗方式-
Gilead Sciences, Inc. (NASDAQ:GILD) will present new data from the company's broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif. Data to be highlighted across three oral presentations include: initial results from two cohorts of the EVOKE-02 study of Trodelvy (sacituzumab govitecan-hziy) in previously untreated advanced or metastatic non-small cell lung cancer (mNSCLC), results from a subgroup analysis of the EVOKE-01 study of Trodelvy in second-line mNSCLC, and updated data from the TROPiCS-03 study of Trodelvy in extensive stage small cell lung cancer (ES-SCLC).
吉利德科学公司（NASDAQ:GILD）将在国际肺癌研究协会举办的2024年国际肺癌大会上公布公司广泛的肺癌临床开发计划的新数据，该大会将于2024年9月7日至10日在加州圣地亚哥举行。通过三个口头报告，将重点介绍以下数据：EVOKE-02研究在先前未接受治疗的晚期或转移性非小细胞肺癌（mNSCLC）的两个队列的初始结果，EVOKE-01研究在二线mNSCLC的分组分析结果，以及TROPiCS-03研究在广泛期小细胞肺癌（ES-SCLC）中的Trodelvy的更新数据。
